Pathophysiology of Myotonia and Periodic Paralysis

肌强直和周期性麻痹的病理生理学

基本信息

  • 批准号:
    10641898
  • 负责人:
  • 金额:
    $ 54.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary / Abstract Periodic paralysis and myotonia are ion channelopathies of skeletal muscle with debilitating episodes of severe weakness lasting hours to days and activity-dependent muscle stiffness. The long-term goal of this project is to advance our understanding of disease mechanism in these disorders of muscle excitability and to apply this knowledge in the design and pre-clinical testing of therapeutic interventions. Much progress has been made in establishing a causal relationship between the biophysical defect of a mutant channel and the clinical phenotype. For example, over 80 missense mutations have been identified in the NaV1.4 sodium channel, and we have shown by functional expression studies, coupled with simulations of fiber excitability, that mutations with gain of function changes (e.g. impaired inactivation) cause hyperkalemic periodic paralysis (HyperPP) with myotonia. Alternatively, the NaV1.4 mutations in hypokalemic periodic paralysis (HypoPP) are all R/X substitutions in S4 segments of voltage sensor domains that share a common functional defect - the anomalous gating pore leakage current. In all forms of periodic paralysis, the transient attacks of weakness result from sustained depolarization of 𝑉𝑟𝑒௦௧ and loss of excitability, which are often triggered by stress, diet (carbohydrate, salt content, fasting), cold temperature, or exercise. The mechanisms by which these triggers destabilize 𝑉𝑟𝑒௦௧, in the setting of a static defect for a mutant channel, are fundamental open questions in the field and also represent opportunities for therapeutic intervention. A major impediment to progress has been the scarce availability of affected muscle. We created three knock-in mutant mouse models of PP that have robust phenotypes for HyperPP (NaV1.4-M1592V) or HypoPP (NaV1.4-R669H; CaV1.1-R528H). These mouse models have led to new insights on disease mechanism (e.g. recovery from acidosis is a potent trigger of HypoPP) and have led to novel therapeutic interventions that are now in clinical trials (bumetanide inhibition of the NKCC1 cotransporter prevents HypoPP). We will extend our investigations of periodic paralysis by focusing on the impact of ion gradients. Changes in extracellular [K+]o are established triggers for HypoPP (low) or HyperPP (high), but relatively little is known about Na+ and Cl- shifts in PP. Limited human data suggest an acute rise of [Na+]in during an episode of HyperPP or chronically high [Na+]in for HypoPP. In addition, we showed that reducing Cl- influx completely prevents HypoPP attacks. We have developed improved ion-selective microelectrodes, that in combination with the unique resource of our knock-in mutant mice, will enable us to (1) characterize muscle fiber Na+ and Cl- content at rest and during an attack of PP, (2) define the contribution of specific ion transport systems (mutant NaV1.4, NKCC1, Na/K-ATPase, Cl- exchangers) in setting ion concentrations in muscle channelopathies, (3) define the functional consequences of ion gradient perturbations in PP, based on computational modeling and simulation, and (4) use these insights in the design and pre-clinical testing of disease-modifying interventions. .
项目总结/摘要 周期性麻痹和肌强直是骨骼肌的离子通道病, 持续数小时至数天的虚弱和活动依赖性肌肉僵硬。该项目的长期目标是 推进我们对这些肌肉兴奋性障碍的疾病机制的理解,并将其应用于 治疗干预措施的设计和临床前测试方面的知识。 在建立一个人的生物物理缺陷与他的疾病之间的因果关系方面已经取得了很大的进展。 突变通道和临床表型。例如,已经鉴定了超过80个错义突变, NaV1.4钠通道,我们已经通过功能表达研究显示,再加上模拟 纤维兴奋性,即具有功能改变增益的突变(例如失活受损)导致高钾血症 周期性麻痹(HyperPP)伴肌强直。或者,低钾血症周期性发作中的NaV1.4突变 麻痹(HypoPP)是电压传感器域的S4片段中的所有R/X置换,其共享共同的 功能缺陷-异常门控孔漏电流。在所有形式的周期性麻痹中, 虚弱的发作是由持续的脑电去极化和兴奋性丧失引起的,𝑉𝑟𝑒 通过压力、饮食(碳水化合物、盐含量、禁食)、寒冷温度或运动。的机制 在突变通道的静态缺陷的设置中,这些触发器不稳定的触发器是基本开放的 这是该领域的问题,也代表了治疗干预的机会。的主要障碍 进展是受影响肌肉的稀缺性。我们建立了三个基因敲入突变小鼠模型 具有HyperPP(NaV1.4-M1592 V)或HypoPP(NaV1.4-R669 H; CaV1.1-R528 H)的稳健表型的PP。 这些小鼠模型导致了对疾病机制的新见解(例如,从酸中毒中恢复是一种有效的治疗方法)。 HypoPP的触发因素),并导致了目前处于临床试验中的新型治疗干预(布美他尼 NKCC 1协同转运蛋白的抑制防止了HypoPP)。 我们将通过关注离子梯度的影响来扩展我们对周期性麻痹的研究。 细胞外[K+]o的变化是HypoPP(低)或HyperPP(高)的触发因素,但相对较少 已知PP中的Na+和Cl-位移。有限的人类数据表明,在一次发作期间, HypoPP或慢性高[Na+]。此外,我们发现完全减少Cl-内流 防止HypoPP攻击。我们已经开发了改进的离子选择性微电极, 我们的基因敲入突变小鼠的独特资源,将使我们能够(1)表征肌纤维Na+和Cl- 含量在休息和攻击期间的PP,(2)定义的贡献,具体的离子转运系统(突变 NaV1.4、NKCC 1、Na/K-ATPase、Cl-交换剂)在肌肉通道病中设定离子浓度,(3) 基于计算建模,定义PP中离子梯度扰动的功能后果, 模拟,以及(4)在疾病改善干预措施的设计和临床前测试中使用这些见解。 .

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Retigabine suppresses loss of force in mouse models of hypokalaemic periodic paralysis.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEPHEN C. CANNON其他文献

STEPHEN C. CANNON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEPHEN C. CANNON', 18)}}的其他基金

Pathophysiology of Myotonia and Periodic Paralysis
肌强直和周期性麻痹的病理生理学
  • 批准号:
    10277079
  • 财政年份:
    2021
  • 资助金额:
    $ 54.61万
  • 项目类别:
Pathophysiology of Myotonia and Periodic Paralysis
肌强直和周期性麻痹的病理生理学
  • 批准号:
    10442584
  • 财政年份:
    2021
  • 资助金额:
    $ 54.61万
  • 项目类别:
Disease Pathogenesis and Modification for CaV1.1-Associated Hypokalemic Periodic
CaV1.1 相关低钾血症周期性疾病的发病机制和修饰
  • 批准号:
    9528467
  • 财政年份:
    2012
  • 资助金额:
    $ 54.61万
  • 项目类别:
Disease Pathogenesis and Modification for CaV1.1-Associated Hypokalemic Periodic
CaV1.1 相关低钾血症周期性疾病的发病机制和修饰
  • 批准号:
    10196933
  • 财政年份:
    2012
  • 资助金额:
    $ 54.61万
  • 项目类别:
Disease Pathogenesis and Modification for CaV1.1-Associated Hypokalemic Periodic
CaV1.1 相关低钾血症周期性疾病的发病机制和修饰
  • 批准号:
    8496723
  • 财政年份:
    2012
  • 资助金额:
    $ 54.61万
  • 项目类别:
Disease Pathogenesis and Modification for CaV1.1-Associated Hypokalemic Periodic
CaV1.1 相关低钾血症周期性疾病的发病机制和修饰
  • 批准号:
    8346112
  • 财政年份:
    2012
  • 资助金额:
    $ 54.61万
  • 项目类别:
Disease Pathogenesis and Modification for CaV1.1-Associated Hypokalemic Periodic
CaV1.1 相关低钾血症周期性疾病的发病机制和修饰
  • 批准号:
    8688911
  • 财政年份:
    2012
  • 资助金额:
    $ 54.61万
  • 项目类别:
Molecular Physiology of Myotonia and Periodic Paralysis
肌强直和周期性麻痹的分子生理学
  • 批准号:
    7820641
  • 财政年份:
    2009
  • 资助金额:
    $ 54.61万
  • 项目类别:
Molecular Physiology of Myotonia and Periodic Paralysis
肌强直和周期性麻痹的分子生理学
  • 批准号:
    8461384
  • 财政年份:
    1994
  • 资助金额:
    $ 54.61万
  • 项目类别:
Molecular Physiology of Myotonia and Periodic Paralysis
肌强直和周期性麻痹的分子生理学
  • 批准号:
    9108578
  • 财政年份:
    1994
  • 资助金额:
    $ 54.61万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.61万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.61万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 54.61万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.61万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 54.61万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.61万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.61万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.61万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 54.61万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 54.61万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了